Literature DB >> 21532804

Commentary: chemotherapy dosing in obese patients with cancer-the need for evidence-based clinical practice guidelines.

Gary H Lyman.   

Abstract

Entities:  

Year:  2011        PMID： 21532804      PMCID： PMC3014503          DOI： 10.1200/JOP.2010.000200

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  16 in total

1.  Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.

Authors:  C Mayers; T Panzarella; I F Tannock
Journal:  Cancer       Date:  2001-06-15       Impact factor: 6.860

2.  Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.

Authors:  Jacques Bonneterre; Henri Roché; Pierre Kerbrat; Alain Brémond; Pierre Fumoleau; Moïse Namer; Marie-Josèphe Goudier; Simon Schraub; Pierre Fargeot; Isabelle Chapelle-Marcillac
Journal:  J Clin Oncol       Date:  2005-04-20       Impact factor: 44.544

3.  Undertreatment of obese women receiving breast cancer chemotherapy.

Authors:  Jennifer J Griggs; Melony E S Sorbero; Gary H Lyman
Journal:  Arch Intern Med       Date:  2005-06-13

4.  Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing.

Authors:  Monique D Lopes-Serrao; Sarah M Gressett Ussery; Ronald G Hall; Sachin R Shah
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

5.  Chemotherapy dosing strategies in the obese, elderly, and thin patient: results of a nationwide survey.

Authors:  Kathryn M Field; Suzanne Kosmider; Michael Jefford; Michael Michael; Ross Jennens; Michael Green; Peter Gibbs
Journal:  J Oncol Pract       Date:  2008-05       Impact factor: 3.840

6.  Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy.

Authors:  Jennifer J Griggs; Eva Culakova; Melony E S Sorbero; Michelle van Ryn; Marek S Poniewierski; Debra A Wolff; Jeffrey Crawford; David C Dale; Gary H Lyman
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

7.  Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens.

Authors:  Jennifer J Griggs; Eva Culakova; Melony E S Sorbero; Marek S Poniewierski; Debra A Wolff; Jeffrey Crawford; David C Dale; Gary H Lyman
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

8.  Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.

Authors:  Gary H Lyman; David C Dale; Jonathan Friedberg; Jeffrey Crawford; Richard I Fisher
Journal:  J Clin Oncol       Date:  2004-09-20       Impact factor: 44.544

9.  Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).

Authors:  E Lepage; C Gisselbrecht; C Haioun; C Sebban; H Tilly; A Bosly; P Morel; R Herbrecht; F Reyes; B Coiffier
Journal:  Ann Oncol       Date:  1993-09       Impact factor: 32.976

10.  Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.

Authors:  Gary H Lyman; David C Dale; Jeffrey Crawford
Journal:  J Clin Oncol       Date:  2003-12-15       Impact factor: 44.544
View more
  3 in total

1.  Weight-based chemotherapy dosing in obese patients with cancer: back to the future.

Authors:  Gary H Lyman
Journal:  J Oncol Pract       Date:  2012-04-03       Impact factor: 3.840

Review 2.  Chemotherapy dosing in overweight and obese patients with cancer.

Authors:  Gary H Lyman; Alex Sparreboom
Journal:  Nat Rev Clin Oncol       Date:  2013-07-16       Impact factor: 66.675

3.  Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.

Authors:  Hélène Bonsang-Kitzis; Léonor Chaltier; Lisa Belin; Alexia Savignoni; Roman Rouzier; Marie-Paule Sablin; Florence Lerebours; François-Clément Bidard; Paul Cottu; Xavier Sastre-Garau; Marick Laé; Jean-Yves Pierga; Fabien Reyal
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.